Methicillin-resistant Staphylococcus aureus surface and secreted antigens (MRSA-SSA)

Methicillin-resistant Staphylococcus aureus (MRSA) surface and secreted antigens encompass a wide array of proteins and polysaccharides that are critical for the pathogen's ability to cause disease. Surface antigens, such as Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) like Clumping factor A (ClfA), allow the bacteria to adhere to host tissues and evade the immune system (PMID: 25103155). Secreted antigens, primarily toxins like alpha-hemolysin (Hla) and Panton-Valentine leukocidin (PVL), are responsible for lysing host cells and driving the inflammatory response (PMID: 24133134). These antigens serve as the primary targets for passive and active immunization strategies, including monoclonal antibodies and multi-component vaccines (PMID: 24595143). Drugs targeting these molecules aim to either neutralize the damaging effects of toxins or block the initial stages of infection by preventing bacterial attachment. Despite significant research, many therapies targeting these antigens have failed in clinical trials, likely due to the functional redundancy of MRSA's virulence factors and the complexity of the host-pathogen interaction (StatPearls).

Other names

MRSA virulence factorsStaphylococcal surface proteins and exotoxinsMRSA antigensStaphylococcus aureus surface and secreted antigens

Neutralization of bacterial toxins and inhibition of bacterial adhesion to host tissues.